Screener
Stoke Therapeutics, Inc. STOK Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other current assets | 6,880 | 4,389 |
| Total current assets | $366,681 | $305,700 |
| Marketable securities - long-term | 67,481 | 106,260 |
| Restricted cash - long-term | 3,227 | 227 |
| Operating lease right-of-use assets | 2,493 | 3,101 |
| Property and equipment, net | 3,395 | 3,146 |
| Total assets | $443,277 | $418,434 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s restricted cash?
- Stoke Therapeutics, Inc. (STOK) reported restricted cash of $3.23M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s restricted cash changed year-over-year?
- Stoke Therapeutics, Inc.'s restricted cash increased by 4202.7% year-over-year, from $75K to $3.23M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s restricted cash has grown at a 19.2% compound annual growth rate (CAGR), from $205K to $494K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Stoke Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude